Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA guides on how AA can be converted to full approval.

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Mar 26, 2023 12:49pm

153 Views

Post# 35361279

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA guides on how AA can be converted to full approval.

ksw,

That is a good question. My GUESS is that it would be the ballpark market price. However, your point would have even more weight if the number of indications were very limited, like just panc or Mbc. It seems there may be more indications as well as CAR-T and other combos. So we are not just multiplying price times quantity. Plus there is the precision medicine side coming from a biomarker.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing